# Mesoblast

the FDA accepted its Biologics License Application for Ryoncil (remestemcel-L) in children with steroid-refractory acute graft-versus-host disease, the lead allogeneic-MSC regulatory asset; remestemcel-L is the most-studied MSC in inflammatory disease.

Source: https://en.bioecon.ru/companies/mesoblast/
Updated: 2026-07-20

- Country: United States
- Ticker: MESO

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Founded | 2004 | https://www.thecompanycheck.com/company/b/mesoblast/jbbzohndvqs6l2fg6 |
| Funding | 16 rounds completed, latest $159.98M Post-IPO | https://www.thecompanycheck.com/company/b/mesoblast/jbbzohndvqs6l2fg6 |
| Headcount | 81 employees (as of June 30, 2025) | https://www.thecompanycheck.com/company/b/mesoblast/jbbzohndvqs6l2fg6 |
| Regulatory approval | FDA approval of Ryoncil (remestemcel-L-rknd) for pediatric SR-aGVHD on December 18, 2024 | https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-remestemcel-l-rknd-steroid-refractory-acute-graft-versus-host-disease-pediatric, https://www.isctglobal.org/telegrafthub/blogs/ken-ip1/2025/02/12/na-lra-watchdog-update-february-2025 |
| Revenue | US$115M Ryoncil net revenue for the first full year post-FDA approval (ended June 30, 2026) | https://www.sec.gov/Archives/edgar/data/1345099/000134509926000072/exhibit991activitystatem.htm |

Independent sources: fda.gov, isctglobal.org, sec.gov, thecompanycheck.com

## Technologies

- [Stem cell therapy for autoimmune disease](https://en.bioecon.ru/technology/stem-cell-therapy-autoimmune/)